Abstract |
The present study is to explore the anticancer effect of loonamycin (LM) in vitro and in vivo, and investigate the underlying mechanism with combined multi-omics. LM exhibited anticancer activity in human triple negative breast cancer cells by promoting cell apoptosis. LM administration inhibited the growth of MDA-MB-468 tumors in a murine xenograft model of breast cancer. Mechanistic studies suggested that LM could inhibit the topoisomerase I in a dose-dependent manner in vitro experiments. Combined with the transcriptomics and proteomic analysis, LM has a significant effect on O- glycan, p53-related signal pathway and EGFR/PI3K/AKT/mTOR signal pathway in enrichment of the KEGG pathway. The GSEA data also suggests that the TNBC cells treated with LM may be regulated by p53, O- glycan and EGFR/PI3K/AKT/mTOR signaling pathway. Taken together, our findings predicted that LM may target p53 and EGFR/PI3K/AKT/mTOR signaling pathway, inhibiting topoisomerase to exhibit its anticancer effect.
|
Authors | Xiao Sun, Zhanying Lu, Zhenzhen Liang, Bowen Deng, Yuping Zhu, Jing Shi, Xiaoling Lu |
Journal | Molecules (Basel, Switzerland)
(Molecules)
Vol. 27
Issue 20
(Oct 17 2022)
ISSN: 1420-3049 [Electronic] Switzerland |
PMID | 36296549
(Publication Type: Journal Article)
|
Chemical References |
- Phosphatidylinositol 3-Kinases
- Proto-Oncogene Proteins c-akt
- rebeccamycin
- DNA Topoisomerases, Type I
- Tumor Suppressor Protein p53
- TOR Serine-Threonine Kinases
- ErbB Receptors
|
Topics |
- Humans
- Mice
- Animals
- Phosphatidylinositol 3-Kinases
(metabolism)
- Proto-Oncogene Proteins c-akt
(metabolism)
- DNA Topoisomerases, Type I
(metabolism)
- Tumor Suppressor Protein p53
(genetics, metabolism)
- Transcriptome
- Proteomics
- Cell Line, Tumor
- TOR Serine-Threonine Kinases
(metabolism)
- Triple Negative Breast Neoplasms
(metabolism)
- Apoptosis
- ErbB Receptors
(genetics, metabolism)
- Cell Proliferation
|